The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Convergent action on AMR identified as an important area of intervention
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
The company has also been named among global sustainability leaders for the 7th year in a row in the Dow Jones Sustainability Index in the Emerging Markets category
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
India now has 648 medical colleges in 2022 with a whopping 96% increase in the number of Government Medical Colleges (GMC) alone and a 42% increase in the private sector, since 2014
The two have agreed to jointly undertake R&D activities on scientific validation of Ayush concepts, procedures and products
Subscribe To Our Newsletter & Stay Updated
